ArticleAnalytical and bioanalytical chemistry2026
Polyclonal antibodies targeting defined epitopes on cancer biomarker MUC16.
Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Measurements of the peptide epitope CA125 are crucial in ovarian cancer care. Despite its value as a tool in disease management, CA125 is an imperfect biomarker, with rates of false positive and false negative response that preclude its use as a screening tool in the general population. The monoclonal antibodies that perform capture and recognition in the CA125 test-OC125 and M11-were developed using complex targets as immunogens and recognize epitopes that have been located on mucin16 (MUC16) but otherwise remain undefined at the molecular level. We hypothesized that new antibodies recognizing MUC16 peptides of known sequence could enable the development of assay platforms that overcome the limitations of the current CA125 test. Here, we report the development and characterization of three sets of polyclonal antibodies that recognize known MUC16 peptides. Peptides that appear several times within MUC16's highly conserved tandem repeat region were used to immunize two sets of rabbits. Affinity-isolated antibodies were characterized by enzyme-linked immunosorbent assay (ELISA) and Western blot. All three peptides were successful antigens, as indicated by the ability of the resulting polyclonal antibodies to bind individually expressed proteins from the MUC16 tandem repeat region. In particular, the polyclonal antibodies raised against peptide 2 (ELGPYTLDRNSLYV) bound to all tandem repeats tested. Peptide 2 antibodies were able to detect intact MUC16 from ovarian cancer cells in a surface plasmon resonance (SPR) assay. In flow cytometry experiments, peptide 2 antibodies bind to MUC16-positive cells (OVCAR3) and do not bind to MUC16-negative cells (OVCAR8). The binding pattern of these polyclonal antibodies opens the possibility of developing new monoclonal antibodies recognizing known epitopes within the tandem repeat region. These reagents may eventually complement or replace the monoclonal antibodies used in the current clinical CA125 test.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.